Related Experiment Videos
[Selected parameters of bone metabolism in hemodialyzed and peritoneally dialyzed patients]
J Małyszko1, E Zbroch, S Wołczyński
1Klinika Nefrologii i Chorób Wewnetrznych Akademii Medycznej w Białymstoku.
Insights
Serum bone markers in end-stage renal failure patients showed no significant differences between hemodialysis and peritoneal dialysis. Both groups exhibited elevated parathyroid hormone and osteocalcin, suggesting increased bone synthesis typical of osteitis fibrosa.
Area of Science:
- Nephrology
- Endocrinology
- Bone Metabolism
Background:
- Renal osteodystrophy is a common complication in end-stage renal failure (ESRD).
- Dialysis modalities, hemodialysis (HD) and continuous ambulatory peritoneal dialysis (CAPD), are used to manage ESRD.
- Comparing bone marker profiles between HD and CAPD patients is crucial for understanding disease progression and management.
Purpose of the Study:
- To compare serum concentrations of key bone markers in ESRD patients undergoing HD versus CAPD.
- To investigate differences in bone metabolism markers between the two primary dialysis treatment groups.
Main Methods:
- Two groups of ESRD patients were studied: 52 on HD and 19 on CAPD.
- Standard laboratory methods and radioimmunoassay were used to measure serum calcium, phosphate, urea, PTH, osteocalcin, 1,25(OH)2D3, and IGF-1.
- ELISA was employed to quantify serum TNF-alpha and IL-1.
Main Results:
- No significant differences were observed in the serum concentrations of studied bone markers between HD and CAPD patients.
- All dialyzed patients demonstrated elevated serum PTH, osteocalcin, and alkaline phosphatase.
- Lower serum IGF-1 and normal serum calcitriol concentrations were noted across both dialysis groups.
Conclusions:
- Dialysis modality (HD vs. CAPD) does not appear to significantly alter serum bone marker profiles in ESRD patients.
- Elevated PTH and osteocalcin levels in dialyzed patients suggest intensified bone synthesis, characteristic of osteitis fibrosa.
- Further research may explore the clinical implications of these bone marker profiles in ESRD patients on different dialysis treatments.
Abstract:
Renal osteodystrophy is a metabolic bone disease occurring in patients with end-stage renal failure. The aim of the study was to compare serum concentrations of some bone markers in hemodialysed (HD) patients and in patients undergoing continuous ambulatory peritoneal dialysis (CADO). We studied two groups of patients with end-stage renal failure: 52 hemodialysed individuals aged 24-74 years and 19 peritoneally dialysed patients aged 20-70 years. Serum calcium and phosphate concentration, cholesterol, triglycerides, total protein, albumin, alkaline phosphatase, urea before and after HD, urea in CADO patients were determined by standard laboratory methods. Serum PTH, osteocalcin, 1,25(OH)2D3 and insulin-like growth factor (IGF-1) concentrations were measured by commercially available radioimmunoassay. Serum tumor necrosis factor (TNF-alpha) and interleukin-1 (IL-1) concentrations were measured by ELISA. There were no differences between serum concentrations of the studied bone markers in hemodialysed patients and CAPD patients. All dialysed patients presented high concentrations of serum PTH, osteocalcin, alkaline phosphatase activity, lower serum IGF-1 concentration and normal serum calcitriol concentration. High serum PTH and osteocalcin concentrations may indicate intensification of bone synthesis, what is typical for osteitis fibrosa.